CN111450048A - Gel for antipyretic patch and preparation method thereof - Google Patents

Gel for antipyretic patch and preparation method thereof Download PDF

Info

Publication number
CN111450048A
CN111450048A CN202010309020.2A CN202010309020A CN111450048A CN 111450048 A CN111450048 A CN 111450048A CN 202010309020 A CN202010309020 A CN 202010309020A CN 111450048 A CN111450048 A CN 111450048A
Authority
CN
China
Prior art keywords
gel
urea
dispersion medium
liquid dispersion
antipyretic patch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010309020.2A
Other languages
Chinese (zh)
Other versions
CN111450048B (en
Inventor
田文超
刘莹艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Yuchun Biotechnology Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010309020.2A priority Critical patent/CN111450048B/en
Publication of CN111450048A publication Critical patent/CN111450048A/en
Application granted granted Critical
Publication of CN111450048B publication Critical patent/CN111450048B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a gel for an antipyretic patch and a preparation method thereof, wherein the gel comprises macromolecules and a liquid dispersion medium and is characterized in that the gel layer contains urea, and the urea content is higher than the solubility of the urea at 37.5 ℃; the colloidal particles or macromolecules can be dispersed or dissolved in a liquid dispersion medium to form a gel. The gel prepared by the application has stable quality, is convenient for continuous production, has stable product quality after being applied to the antipyretic patch, and can not cause the problems of aggravation of diseases, cough, throat inflammation and the like.

Description

Gel for antipyretic patch and preparation method thereof
Technical Field
The invention relates to a gel for an antipyretic patch and a preparation method thereof.
Background
The gel that current subsides of bringing down a fever usefulness is mostly constituteed by water and polymer, utilizes the evaporation of water to take away the heat to reach the purpose of cooling, in order to reach better cooling effect, explore and add the heat absorbent in the gel, like the preparation method of an intelligence children subsides of bringing down a fever, patent number: 2016102500843, the solubility of urea in the heat absorbent is high, and the quantity of absorbed heat is large, however, because the solubility of urea is high, the precipitation and dissolution quantity of urea are large along with the change of temperature, therefore, during the actual production, the problem of urea precipitation in the process of cooling gel exists, the problem of inconsistent urea content in the upper layer, the middle layer and the lower layer of the prepared gel exists, the quality of the prepared cooling patch is inconsistent, and the batch production is troublesome.
Meanwhile, the prepared antipyretic patch is sold to an object of a pharmacy instead of a direct user, so that the problem of storage exists, the fact that the antipyretic patch added with urea has quality change in the storage process and even has pharmacy reaction, and the antipyretic patch added with urea with good cooling effect has the most complaints on the contrary because the user uses the antipyretic patch added with urea even aggravates the disease, has slight fever without the problems of cough and throat inflammation, has the problems of cough and throat inflammation after using the antipyretic patch, and brings difficulty to the popularization of the functional antipyretic patch with better cooling effect.
The stability of the quality of the gel determines the stability of the quality of the antipyretic patch and determines whether the product can be popularized in the market and occupies a place, so that the market needs a gel with stable quality during production, the gel can be produced in batches, and meanwhile, the gel is applied to the antipyretic patch, can also keep better stability, does not aggravate illness, and does not cause the problems of cough and throat inflammation.
Disclosure of Invention
The technical problem to be solved by the present application is to provide a gel for an antipyretic patch and a preparation method thereof, and the technical problem 1) solved by the present application is to provide a preparation method of the gel, wherein the gel prepared by the method has stable quality and can be produced in batch, and meanwhile, the antipyretic patch prepared by the gel prepared by the method has stable quality, can not aggravate illness conditions and can not cause cough and throat inflammation.
In order to solve the technical problems, the invention adopts the following technical scheme:
a gel for antipyretic patch comprises polymer, liquid dispersion medium, and urea, wherein the urea content is greater than its solubility at 37.5 deg.C; the polymer can be dispersed or dissolved in a liquid dispersion medium to form a gel.
The pH value of the gel is 6.5-8.5.
The liquid dispersion medium is one of water or an aqueous solution.
The liquid dispersion medium is a buffer solution, and the pH value of the buffer solution is 6.5-8.5.
The polymer is one or more of gelatin, carbomer and polyvinyl alcohol.
The polymer is carbomer.
A preparation method of the gel for the antipyretic patch comprises the following steps: heating the liquid dispersion medium;
adding urea to dissolve the urea;
adding polymer, dissolving or mixing to obtain mixture;
and (4) gelling.
The heating temperature is 37.5-42 ℃,
the gel was allowed to cool and the mixture was rendered non-flowable within 1 minute.
The heating temperature is 37.5-42 ℃; the gel is kept at the same temperature, and alkali is added to make the mixture lose fluidity.
The invention has the following beneficial technical effects:
1. since the gel is made to lose fluidity in one minute, the present application can ensure stable quality of the gel.
2. The buffer solution used in the present application can make the gel product more stable.
3. Carbomer is preferably selected as the polymer, the temperature is kept unchanged, and the mixture is gelled by adding alkali, so that no crystal is precipitated in the gelling process, the quality of the gelled product can be better stabilized, and the carbomer is superior to other polymers needing cooling gel.
4. This application adds the solubility of urea content when being greater than its 37.5 ℃, and this is set for more than 37.2 by human fever temperature, even when using this article, because the influence of human temperature makes the urea in the gel dissolve to absorb the heat cooling better, can also carry out intelligent cooling according to the difference of fever temperature.
Detailed Description
The present invention is further illustrated by the following specific examples.
Example 1
A gel for antipyretic patch comprises polymer, liquid dispersion medium, and urea, wherein the urea content is its solubility at 40 deg.C; urea solubility at 40 ℃ was 129g of urea dissolved in 100g of water.
The gel pH was 8.2.
The liquid dispersion medium is a buffer solution, and the buffer solution is a barbiturate sodium-hydrochloric acid buffer solution having a pH of 8.2.
The polymer is carbomer.
The gel was run according to the following steps: heating the buffer solution to 40 ℃ and maintaining;
adding urea to dissolve the urea;
adding carbomer 1/20 in water, keeping the temperature constant, adding 10% sodium hydroxide solution to pH of 8.2, stirring, and gelling.
Example 2
A gel for antipyretic patch comprises polymer, liquid dispersion medium, and urea, wherein the urea content is its solubility at 40 deg.C; urea solubility at 40 ℃ was 129g of urea dissolved in 100g of water.
The gel pH was 8.2.
The liquid dispersion medium is water.
The polymer is carbomer.
The gel was run according to the following procedure: heating water to 40 deg.C, and maintaining;
adding urea to dissolve the urea;
adding carbomer 1/20 in water, keeping the temperature constant, adding 10% sodium hydroxide solution to pH of 8.2, stirring, and gelling.
Example 3
A gel for antipyretic patch comprises polymer, liquid dispersion medium, and urea, wherein the urea content is its solubility at 40 deg.C; urea solubility at 40 ℃ was 129g of urea dissolved in 100g of water.
The liquid dispersion medium is water; the polymer is gelatin.
The gel was run according to the following procedure: heating water to 40 deg.C, and maintaining;
adding urea to dissolve the urea;
adding 2/1000 gelatin (water), and stirring to obtain mixture;
cool and gel the mixture in one minute.
Example 4
A gel for antipyretic patch contains polymer, liquid dispersion medium, and urea with solubility at 39 deg.C.
The gel pH was 7.8.
The liquid dispersion medium was a barbiturate sodium-hydrochloric acid buffer solution having a pH of 7.8.
The gel also contains adjuvant treatment medicine, and the adjuvant treatment medicine is lavender essential oil.
The gel in the gel layer is carried out according to the following steps: heating the buffer solution to 40 ℃ and maintaining;
adding urea to dissolve the urea;
adding lavender essential oil, and uniformly dispersing;
adding 6% polyvinyl alcohol aqueous solution, and mixing uniformly to obtain a mixture;
cooling and gelling.
The gel caused the mixture to lose fluidity within 1 minute.
Example 5
A gel for antipyretic patch comprises polymer, liquid dispersion medium, and urea, wherein the urea content is its solubility at 40 deg.C; urea solubility at 40 ℃ was 129g of urea dissolved in 100g of water.
The gel pH was 8.0.
The liquid dispersion medium is a buffer solution, and the buffer solution is a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution having a pH of 8.0.
The polymer is carbomer.
The gel was run according to the following steps: heating the buffer solution to 40 ℃ and maintaining;
adding urea to dissolve the urea;
adding carbomer 1/20 in water, keeping temperature, adding triethanolamine to pH 8.0, stirring, and making gel.
The beneficial effects of the present invention are further illustrated below in conjunction with experimental data:
experiment one
1. Experimental materials
1, materials and methods:
1.1 test site: binzhou medical school.
1.2 test materials: the gel prepared in example 1, the gel prepared in example 2, the gel prepared in example 3 and comparative example 1 were prepared in the same manner as in example 3 except that the gel was prepared at 5 minutes.
1.3 Observation and detection: observing the phenomenon after the gelation and detecting the content of urea.
1.4 Experimental design: observing the gel phenomenon, and detecting the N content after the gel preparation is finished.
And (3) detecting the urea content: the detection is carried out according to the detection method of GB/T2440-2017 urea.
The experiment was conducted in a consistent manner except for the different treatments used in the experiment.
2 results and analysis
The initial urea content, the final urea content and the experimental phenomena are shown in Table 1
TABLE 1
Figure 1
As can be seen from the experimental data in Table 1, the mixture is made into gel by adding alkali while the temperature is kept unchanged, so that the quality of the upper layer, the middle layer and the lower layer of the gel can be kept stable; the mixture loses fluidity within 1 minute, so that the upper layer, the middle layer and the lower layer of the product have not very big difference but have difference, while the difference of the upper layer, the middle layer and the lower layer of the product is larger and the quality is unstable when the comparison 1 (the preparation method of the gel, except the gel at 5 minutes, is the same as the example 3).
Experiment two
1, materials and methods:
1.1 test site: binzhou medical school.
1.2 test materials: the heat patch prepared in example 1 and the heat patch prepared in example 2 were used.
1.3 Experimental design: the prepared cooling patch of example 1, the cooling patch of example 2 and comparative example 2 (except that the amount of sodium hydroxide added was as much as in example 1, the other preparation methods were the same as those of example 2, and the pH was measured to be 9.2), 10 sheets were taken for each set of experiments, placed in a refrigerating and heating cabinet, adjusted to 40 ℃ for 20min, measured and recorded the temperature of the cooling patch using an infrared temperature measuring gun, recorded as M1, adjusted to 15 ℃, stored in the refrigerating and heating cabinet for 2 months, adjusted the temperature of the refrigerating and heating cabinet to 40 ℃ for 20min, and measured and recorded the temperature of the cooling patch using an infrared temperature measuring gun, recorded as M2.
The experiment was conducted in a consistent manner except for the different treatments used in the experiment.
2 results and analysis
The detection temperature of each group of fever cooling pastes is shown in the table 2
TABLE 2
Example 1M1 (. degree. C.) Example 2M1 (. degree. C.) Comparative 2M2 (. degree.C.) Example 1M2 (. degree. C.) Example 2M2 (. degree. C.) Comparative 2M2 (. degree.C.)
Sample 1 38.6 38.7 38.6 38.6 38.9 39.4
Sample 2 38.6 38.6 38.6 38.6 38.9 39.5
Sample 3 38.6 38.6 38.6 38.7 39.0 39.6
Sample 4 38.6 38.7 38.6 38.6 38.9 39.5
Sample 5 38.7 38.6 38.7 38.7 38.9 39.4
Sample 6 38.6 38.6 38.7 38.6 39.0 39.5
Sample 7 38.7 38.6 38.7 38.7 38.9 39.4
Sample 8 38.6 38.6 38.6 38.6 39.0 39.5
Sample 9 38.6 38.6 38.6 38.6 38.9 39.4
Sample 10 38.6 38.7 38.6 38.7 38.9 39.5
As can be seen from Table 2, the effect of example 1 of the present application is basically unchanged with the prolonging of the storage time, while the effect of example 2 is obviously changed with the prolonging of the storage time, and the change of comparison 2 is obvious, which shows that the using effect of the present application is influenced by both the liquid dispersion medium and the pH.

Claims (9)

1. A gel for an antipyretic patch comprises a macromolecule and a liquid dispersion medium, and is characterized by also comprising urea, wherein the urea content is greater than the solubility of the urea at 37.5 ℃; the polymer can be dispersed or dissolved in a liquid dispersion medium to form a gel.
2. The gel for a cooling patch according to claim 1, wherein the gel has a pH of 6.5 to 8.5.
3. The antipyretic patch gel according to claim 1 wherein said liquid dispersion medium is one of water or an aqueous solution.
4. The gel for an antipyretic patch according to any one of claims 1 to 3, wherein said liquid dispersion medium is a buffer solution, and said buffer solution has a pH of 6.5 to 8.5.
5. The gel for an antipyretic patch according to any one of claims 1 to 3, wherein said polymer is one or more of gelatin, carbomer and polyvinyl alcohol.
6. The gel for an antipyretic patch according to any one of claims 1 to 3, wherein said polymer is carbomer.
7. The preparation method of the gel for the cooling paste is characterized by comprising the following steps of: heating the liquid dispersion medium;
adding urea to dissolve the urea;
adding polymer, dissolving or mixing to obtain mixture;
and (4) gelling.
8. The method for preparing a gel for an antipyretic patch according to claim 7, wherein said heating temperature is 37.5 ℃ to 42 ℃,
the gel was allowed to cool and the mixture was rendered non-flowable within 1 minute.
9. The method for preparing the gel for the cooling patch as claimed in claim 7, wherein the heating temperature is 37.5 ℃ to 42 ℃; the gel is kept at the same temperature, and alkali is added to make the mixture lose fluidity.
CN202010309020.2A 2020-04-19 2020-04-19 Gel for antipyretic patch and preparation method thereof Active CN111450048B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010309020.2A CN111450048B (en) 2020-04-19 2020-04-19 Gel for antipyretic patch and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010309020.2A CN111450048B (en) 2020-04-19 2020-04-19 Gel for antipyretic patch and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111450048A true CN111450048A (en) 2020-07-28
CN111450048B CN111450048B (en) 2023-12-22

Family

ID=71671038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010309020.2A Active CN111450048B (en) 2020-04-19 2020-04-19 Gel for antipyretic patch and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111450048B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104337796A (en) * 2014-10-12 2015-02-11 浙江欧洁科技股份有限公司 Polymeric hydrogel fever cooling patch for children and preparation method thereof
CN105687446A (en) * 2016-04-21 2016-06-22 吴美燕 Preparation method of intelligent traditional Chinese medicine fever abatement paste
CN105878218A (en) * 2016-04-21 2016-08-24 吴美燕 Preparation method of intelligent children's fever cooling patch
WO2016141755A1 (en) * 2015-03-12 2016-09-15 施敬东 Medical defervescence patch and preparation method therefor
CN105998251A (en) * 2016-06-17 2016-10-12 刘泰 Preparation method of antipyretic patch
WO2020051914A1 (en) * 2018-09-14 2020-03-19 湖南新金辐医疗科技有限公司 Antipyretic patch and preparation method therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104337796A (en) * 2014-10-12 2015-02-11 浙江欧洁科技股份有限公司 Polymeric hydrogel fever cooling patch for children and preparation method thereof
WO2016141755A1 (en) * 2015-03-12 2016-09-15 施敬东 Medical defervescence patch and preparation method therefor
CN105687446A (en) * 2016-04-21 2016-06-22 吴美燕 Preparation method of intelligent traditional Chinese medicine fever abatement paste
CN105878218A (en) * 2016-04-21 2016-08-24 吴美燕 Preparation method of intelligent children's fever cooling patch
CN105998251A (en) * 2016-06-17 2016-10-12 刘泰 Preparation method of antipyretic patch
WO2020051914A1 (en) * 2018-09-14 2020-03-19 湖南新金辐医疗科技有限公司 Antipyretic patch and preparation method therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
汪亚飞等: "中药经皮给药凝胶剂的研究进展", 今日药学 *

Also Published As

Publication number Publication date
CN111450048B (en) 2023-12-22

Similar Documents

Publication Publication Date Title
CN102362853B (en) Genipin cross-linked soybean protein based theophylline controlled-release gel preparation and preparation method thereof
JP2023027088A (en) Process for making pullulan
JP2022552120A (en) Large spherical salt and its preparation method
CN106606476A (en) Ibuprofen suspension drops and preparation method thereof
CN103494774B (en) Preparation method of decoquinate dry suspension
CN113353941B (en) Medical silicon dioxide adsorbent and preparation method thereof
CN111450048A (en) Gel for antipyretic patch and preparation method thereof
CN113288865B (en) Preparation method of progesterone vaginal gel
CN105535018A (en) Calcium carbonate D3 granules and preparation method thereof
CN110403913B (en) Amantadine hydrochloride soft capsule and preparation method thereof
CN115401209A (en) Preparation method of nano silver powder with controllable particle size
CN108066283A (en) A kind of preparation method of hydrochloric acid Levobetaxolol eye drops
CN102643214B (en) The preparation method of the big crystal grain of Vorinostat I crystal form and preparation
CN102349875A (en) Preparation method of methylsulfonic acid imatinib tablet
CN112079887A (en) Puerarin monohydrate single crystal and preparation method and application thereof
CN108451904B (en) Potassium oxonate stable suspension and preparation method thereof
CN115487153B (en) Method for protecting crystal forms of compounds
CN106913544A (en) A kind of Gefitinib tablet of Fast Stripping and preparation method thereof
CN105597101A (en) Innovative pharmaceutic adjuvant colloidal microcrystalline cellulose and preparation method thereof
US3247078A (en) Process for the propagation of microorganisms using a matrix of poly
WO2020216334A1 (en) Bpa lyophilized preparation and preparation method therefor
CN103479605B (en) A kind of dilutable ibuprofen medicinal composition and preparation method thereof
US2486216A (en) Microbiological media
CN113476397B (en) Metronidazole gel and preparation method thereof
CN104557585B (en) Tetracaine hydrochloride crystal, the composition containing tetracaine hydrochloride and preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Tian Wenchao

Inventor after: Liu Xianxian

Inventor after: Liu Yingyan

Inventor before: Tian Wenchao

Inventor before: Liu Yingyan

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20231122

Address after: No. 3, Jingbei Road, Jifeng Village, Zhongxin Town, Zengcheng District, Guangzhou, Guangdong 510000

Applicant after: GUANGZHOU YUCHUN BIOTECHNOLOGY Co.,Ltd.

Address before: 256600, No. two, 661 the Yellow River Road, Bincheng District, Shandong, Binzhou

Applicant before: Tian Wenchao

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant